



徐渴陽

☎ 電話：68068641

♂ 性別：男

職稱：助理教授、主治醫師

✉ 郵箱：kyxu@must.edu.mo

📅 出生年月：1993.05.31

👤 研究領域及方向

代謝性疾病及惡性腫瘤的中西醫結合基礎與臨床研究，包括中醫藥抗代謝、腫瘤的機制機理研究及其活性成分挖掘；基於多組學及細胞外囊泡探索代謝相關炎症、纖維化和惡性腫瘤的機制機理；開發細胞外囊泡靶向載藥系統。

🎓 教育經歷

2024.05-2024.11

悉尼大學

Storr liver center 訪問學者

2021.9-2024.10

香港浸會大學

中醫學與生物醫學 | 哲學博士

博導：關曉儀副教授（教學科研部副主任，中醫藥學院）

共同博導：呂愛平教授（歐洲科學院院士，副校長-研究及拓展，中醫藥學院署理院長及講座教授，黃英豪博士中醫藥教授）

2016.9-2019.6

浙江中醫藥大學

中西醫結合臨床 | 醫學碩士（學術型）

碩導：包劍鋒教授（杭州市西溪醫院院長助理，科教科主任，中醫科主任）

合作導師：喬梁教授（Storr liver center, WIMR, 悉尼大學）

2011.9-2016.6

成都中醫藥大學

中西醫結合臨床 | 醫學學士

💼 工作經歷

2025.01-至今

澳門科技大學

中醫藥學院：助理教授

2020.9-2021.08

香港浸會大學

中醫藥學院：研究助理

2019.8-2020.8

杭州濱江綠康康復醫院

老年康復科：內科醫生

研究項目

探索脂肪細胞外泌體來源的 ARF1/MAP3K 介導的肝纖維化作用機制（廣東省自然基金 2023A1515011811，參與，在研）

WNT974 and artesunate exhibit synergy in inhibiting colorectal cancer growth by increasing KRAS protein degradation（Medical Health Research Foundation of Hong Kong SAR 08193596，參與，在研）

The role of adipose tissue-derived exosomes in high fat diet-enhanced colorectal cancer metastasis（HKBU Initiation Grant for Faculty Niche Research Areas (FNRA-IG): RC-FNRA-IG/2021/SCM/01，參與，已結題）

基于不同部位脂肪组织来源外泌体的蛋白质整体研究其对肥胖症的影响（深圳市科技創新局項目 #2021Szvup131，參與，已結題）

LncBRM 介導的 RBMY1A1 蛋白促進男性肝癌進展及轉移的作用機制研究（浙江省自然基金 LSY19H030002，參與，已結題）

CHI3L1 在 ALT 異常的慢乙肝及攜帶者中臨床診斷價值（浙江省醫學會 2019KY532，參與，已結題）

學術兼職

The Good Practice in Traditional Chinese Medicine Research Association **Membership**

Student networks on EVs **Membership**

Frontiers in Nutrition **Associated editor**

Frontiers in Oncology **Review editor**

Journal of Taibah University for Science **Editor**

榮譽獲獎

Researcher scholarship of 2024 ISEV Annual Meeting (2024 年國際外泌體大會研究員獎)

第六屆浙江省互聯網+挑戰杯銅獎 排名第三

浙江中醫藥大學十佳學術之星, 2020

代表作(* 共同貢獻, #通訊作者)

1. **Xu KY**, Fu A, Li ZY, Miao LB, Lou ZH, Jiang KY, Lau C, Su T, Tong TJ, Bao JF, Lyu AP, Kwan HY. Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. **Nat Commun.** 2024; 15, Article number: 1685 (2024) (**IF=16.6**, 第一作者)

2. Guo X, Asthana P, Gurung S, Zhang S, Wong SKK, Fallah S, Chow CFW, Che S, Zhai L, Wang Z, Ge X, Jiang Z, Wu J, Zhang Y, Wu X, **Xu KY**, Lin CY, Kwan HY, Lyu A, Zhou Z, Bian ZX, Wong HLX. Regulation of age-associated insulin resistance by MT1-MMP-mediated cleavage of insulin receptor. **Nat Commun.** 2022 Jun 29;13(1):3749. doi: 10.1038/s41467-022-31563-2. (**IF=14.919**, 共同作者)

3. Li Y, Wang J, Huang C, Shen M, Zhan HK#, **Xu KY**#. RNA N6-methyladenosine: a promising

molecular target in metabolic diseases. **Cell Biosci.** 2020 Feb 21; 10:19. doi: 10.1186/s13578-020-00385-4. Review (IF=7.133, 共同通訊作者排名 1)

4. Zhou ZW, Zheng W, Xiang Z, Ye CS, Yin QQ, Wang SH, Xu CA, Wu WH, Hui TC, Wu QQ, Zhao LY, Pan HY#, Xu KY#. Clinical implications of exosome-derived noncoding RNAs in liver. **Lab Invest.** 2022 May;102(5):464-473. doi: 10.1038/s41374-021-00723-1. Review (IF=5.662, 共同通訊作者排名 1)

5. Xu KY*, Liu SR*, Zhao X*, Zhang X, Fu X, Zhou Y, Xu KC, Miao L, Li Z, Li Y, Qiao L, Bao JF. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. **Biomed Pharmacother.** 2019 Feb;110: 844-849. doi: 10.1016/j.biopha.2018.12.039. (IF=3.457, 共一第一)

6. Xu KY*, Zhao X*, Fu X, Xu KC, Li Z, Miao L, Li Y, Cai Z, Qiao L, Bao J. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. **Biomed Pharmacother.** 2019 Sep; 117:109158. doi: 10.1016/j.biopha.2019.109158. (IF=4.545, 共同第一作者排名 1)

7. Xu KC, Sun Y, Sheng B, Zheng Y, Wu X, Xu KY#. Role of identified RNA N6-methyladenosine methylation in liver. **Anal Biochem.** 2019 Aug 1; 578:45-50. doi: 10.1016/j.ab.2019.05.005. Review (IF=2.877, 通訊作者)

8. Zhu L, Zhao LY, Wang Q, Zhong S, Guo XM, Zhu Y, Bao JF#, Xu KY#, Liu SR#. Circulating exosomal miRNAs and cancer early diagnosis. **Clin Transl Oncol.** 2022 Mar;24(3):393-406. doi: 10.1007/s12094-021-02706-6. Review (IF=3.405, 共同通訊作者排名 2)

9. Lou ZH*, Xu KY*, Qiao L*, Su* XQ, OuYang Y, Miao LB, Liu F, Wang Y, Fu A, Ren XH, Huang JS, Li ZY, Bao JF. Diagnostic Potential of the Serum lncRNAs HOTAIR, BRM and ICR for Hepatocellular Carcinoma. **Front Biosci (Landmark Ed)** 2022, 27(9), 264. (IF=3.115, 共同第一作者排名 2)

10. Li Y*, Xu KY*, Xu KC, Chen S, Cao Y, Zhan H. Roles of Identified Long Noncoding RNA in Diabetic Nephropathy. **J Diabetes Res.** 2019 Feb 12; 2019:5383010. doi: 10.1155/2019/5383010. (IF=3.04, 共同第一作者排名 2)

11. Cai Z*, Xu KY*, Li Y, Lv Y, Bao J, Qiao L. Long noncoding RNA in liver cancer stem cells. **Discov Med.** 2017 Sep;24(131):87-93. PMID: 28972877. (IF=2.4, 共同第一作者排名 2)

其他文章列表 (* 共同貢獻)

12. Qiang Wang, Henrik Nilsson, KY Xu, Xufu Wei, Danyu Chen, Dongqin Zhao, Xiaojun Hu, Anrong, Wang, Guojie Bai. Exploring tumor heterogeneity in colorectal liver metastases by imaging: Unsupervised machine learning of preoperative CT radiomics features for prognostic stratification. **European Journal of Radiology.** 2024, 175, 111459. <https://doi.org/10.1016/j.ejrad.2024.111459>. (IF=3.09, 共同作者)

13. Di H, Wang S, Xu C, Yin Q, Xu KY, Zheng W. Shared Genetic Links Between Nonalcoholic

Fatty Liver Disease and Coronary Artery Disease. **Glob Heart**. 2024 Nov 26;19(1):88. doi: 10.5334/gh.1374. (IF=3.0, 共同作者)

14. Yajing He*, Cunsi Ye*, Xu KY, Lili Yang, Kaile Wang, Xiaomei Wang, Meiyu Li, Yu Wu, Qisu Ying, Ming Wang, Shijian Quan and Xiu Yang. Risk Factors and Survival Analysis of Haemodialysis Complicated with Infective Endocarditis. **Exp Ther Med**. 2023, 25(5): 1-8. DOI: 10.3892/etm.2023.11902. (IF=2.751, 共同作者)

15. Fan X, Meng M, Li B, Chen H, Tan J, Xu KY, Xiao S, Kwan HY, Liu Z, Su T. Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay. **J Transl Med**. 2023 Apr 16;21(1):260. doi: 10.1186/s12967-023-04087-6. PMID: 37062842; PMCID: PMC10105967. (IF=7.40, 共同作者)

16. Chen M, Zhang F, Chen B, Lau C, Xu KY, Tong T, Huo C, Han Q, Su T, Kwan HY. Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots. **Cell Mol Life Sci**. 2022 Oct 28;79(11):570. doi: 10.1007/s00018-022-04597-4. (IF=9.261, 共同作者)

17. An L, Zhang M, Lin YF, Jiang T, Xu KY, Xiao SL, Cai LM, Kwan HY, Liu ZQ, Su T. Morroniside, a novel GATA3 binding molecule, inhibits hepatic stellate cells activation by enhancing lysosomal acid lipase expression. **Phytomedicine**. 2022-08. DOI: 10.1016/j.phymed.2022.154199. (中科院 1 区 IF=6.656, 共同作者)

18. Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. **World J Gastrointest Oncol**. 2022 Jan 15;14(1):253-264. doi: 10.4251/wjgo.v14.i1.253. (IF=3.393, 共同作者)

19. Kwan HY, Chen MT, Xu KY, Chen BS. The impact of obesity on adipocyte-derived extracellular vesicles. **Cell Mol Life Sci**. 2021 Dec;78(23):7275-7288. doi: 10.1007/s00018-021-03973-w. Review (IF=9.261, 共同作者)

20. Hu X, Fatima S, Chen MT, Xu KY, Huang CH, Gong RH, Su T, Wong HLX, Bian ZX, Kwan HY. Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism. **Cell Death Dis**. 2021 Aug 12;12(8):791. doi: 10.1038/s41419-021-04076-x. (IF=8.469, 共同作者)

21. Xu BJ, Wang L, Zhan HK, Liangbin Zhao, Yuehan Wang, Meng Shen, Xu KY, Li Li, Xu Luo, Shasha Zhou, Anqi Tang, Gang Liu, Lu Song, Yan Li. Investigation of the Mechanism of Complement System in Diabetic Nephropathy via Bioinformatics Analysis. **J Diabetes Res**. 2021. <https://doi.org/10.1155/2021/5546199>. (IF=4.061, 共同作者)

22. Yan Li, Lei Wang, Bojun Xu, Liangbin Zhao, Li Li, KY Xu, Anqi Tang, Shasha Zhou, Lu Song, Xiao Zhang, Huakui Zhan. Based on Network Pharmacology Tools to Investigate the Molecular Mechanism of Cordyceps sinensis on the Treatment of Diabetic Nephropathy. **J Diabetes Res**, 2021. <https://doi.org/10.1155/2021/8891093>. (IF=4.061, 共同作者)

23. Liu S, Guo R, Hou X, Zhang Y, Jiang X, Wang T, Wu X, Xu KY, Pan X, Qiao L. Adipose-tissue derived porcine mesenchymal stem cells efficiently ameliorate CCl4-induced acute liver failure in mice. **Cytotechnology**. 2020 Jun;72(3): 327-341. doi: 10.1007/s10616-020-00370-2. (IF=2.058, 共同作者)

SCI 審稿雜誌列表

Cancer letter, Laboratory investigation, Phytomedicine, Analytical Cellular Pathology, Cell cycle, Carcinogenesis, Frontier in Genetics, Frontiers in Pharmacology, Therapeutic Advances in Gastroenterology, Liver international, Journal of Hepatocellular Carcinoma, Frontier in oncology, Journal of Taibah University for Science